-

Bruker Announces SciY™ Platform of Advanced Scientific and Automation Software Solutions for the Digital Transformation of the Life Science and Biopharma Industries

ZUERICH, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the SciY™ platform of advanced, vendor-agnostic software solutions for data analysis, data management, research lab and bioproduction QC digitalization, and workflow automation in the life science industry and for biopharma companies. The new SciY platform combines and integrates high-performance lab software solutions for a more comprehensive, vendor-agnostic suite of software and automation solutions for life-science industry customers, primarily in the biopharma sector.

SciY is being launched by Bruker’s new Integrated Data Solutions division, in close collaboration with majority-owned software companies Mestrelab Research, Arxspan, Optimal Industrial Technologies and ZONTAL, along with biopharma automation company Optimal Industrial Automation. With its innovative, modular software solutions, the SciY product platform will streamline data acquisition, integration and interpretation, and enhance the value of data in life-science and biopharma research, development and manufacturing.

SciY encompasses a software portfolio of Electronic Lab Notebook solutions, analytical chemistry and biology solutions, Process Analytical Technologies (PAT), and scientific data management. By automating and digitalizing workflows for generating, analyzing, and utilizing scientific data, customers can achieve results faster, more cost-effectively and conveniently, enabling better and faster decision-making, with high quality, compliance, and AI machine-learning.

Dr. Santi Dominguez, President of the new Bruker Integrated Data Solutions division, commented: "By developing and utilizing the synergetic capabilities of best-in-class teams and software products at Mestrelab, ZONTAL, Arxspan, and Optimal, our SciY platform is reshaping research and development activities in the biopharma and life science industries. The SciY platform of vendor-agnostic software solutions allows the integration of our customers’ physical laboratory instruments and automation hardware with their scientific research, development and manufacturing data into a digital environment to deliver maximum value with minimum effort and disruption. We are aiming to support our clients in their digitalization to drive seamless innovation for accelerating the time to market for new drugs, to automate life-science lab and manufacturing QC processes, and to support efficacy and patient safety.”

Dr. Falko Busse, President of the Bruker BioSpin Group, added: “With SciY and our commitment to provide instrument agnostic software for automation, integration, innovation, and discovery, we enable the life-science and biopharma industry collaboration, enhance the full potential of research data, and advance the digital transformation of the life-science industry. SciY provides many digital end-to-end solutions for life-science research and development, as well as manufacturing automation and QC.”

SciY is combining advanced software technologies into a set of modular solutions to support smooth chemistry and biology experimental design, data acquisition, integration and interpretation, and the management of many analytical instruments, available from various vendors.

About SciY™

SciY is a vendor-agnostic advanced platform offering a broad range of software solutions across the life sciences research, development and manufacturing automation and QC functions – easy to integrate, flexible, user-centric and uncompromisingly performant. By streamlining data analysis and management, SciY empowers scientists and researchers, accelerates scientific discoveries and enables precise decision-making. SciY is a brand of Bruker Integrated Data Solution division that was born from collaborations and majority-acquisitions of renowned vendor-agnostic software partners. www.sciy.com

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Investor:
Justin Ward
Sr. Director, Investor Relations & Corporate Development Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Investor:
Justin Ward
Sr. Director, Investor Relations & Corporate Development Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Media:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...

Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

THUN, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of an additional 60% ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker’s ownership to 100%. The transaction adds ultra-fast TOF-MS technology for small-molecule markets, including atmospheric chemistry research, air quality monitoring, exposomics, foods, flavors &a...

Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events...
Back to Newsroom